{"id":"NCT02739984","sponsor":"Amgen","briefTitle":"Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia","officialTitle":"A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Evolocumab (AMG 145) on LDL-C in Subjects With Type 2 Diabetes Mellitus and Hypercholesterolemia/Mixed Dyslipidemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-05-17","primaryCompletion":"2017-08-03","completion":"2017-08-03","firstPosted":"2016-04-15","resultsPosted":"2018-08-31","lastUpdate":"2018-08-31"},"enrollment":424,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypercholesterolemia","Mixed Dyslipidemia","Type 2 Diabetes"],"interventions":[{"type":"BIOLOGICAL","name":"Evolocumab","otherNames":["Repatha","AMG 145"]},{"type":"DRUG","name":"Placebo to Evolocumab","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Evolocumab","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the effect of 12 weeks of subcutaneous evolocumab taken monthly compared with subcutaneous placebo taken monthly on low density lipoprotein cholesterol (LDL-C) in adults with type 2 diabetes mellitus and high blood cholesterol on a maximally tolerated oral dose of statin of at least moderate-intensity.","primaryOutcome":{"measure":"Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12","timeFrame":"Baseline and Weeks 10 and 12","effectByArm":[{"arm":"Placebo","deltaMin":-0.84,"sd":1.76},{"arm":"Evolocumab","deltaMin":-64.98,"sd":1.31}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":5},"locations":{"siteCount":66,"countries":["United States","Belgium","Canada","Italy","Mexico","Poland","Spain"]},"refs":{"pmids":["36435949","30953107"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":141},"commonTop":["Diabetes mellitus","Hypertension","Diarrhoea","Viral upper respiratory tract infection","Headache"]}}